NOTICE OF UPGRADE

Our websites will be unavailable between the hours of AEST 4AM September 17, 2022 and AEST 11PM on date September 18, 2022

InvestoGain Australia
 

SEARCH LISTED COMPANY


Any AUS or NZ company

Browse Australian listed companies

0-9A B C D E F G H I J K L M N O P Q R S T U V W XY Z

Browse current Australian managed funds

0-9A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

SEARCH PRIVATE COMPANY


SEARCH FUNDS

Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:

CELLMID LIMITED (CDY)

Click here for free access to this company's:
ASX, Legal & CGT Status

Former (or subsequent) names

 FROMTO
ANAGENICS LIMITED15/12/2021
CELLMID LIMITED20/11/200915/12/2021
MEDICAL THERAPIES LIMITED20/11/2009

Shareholder links

Our website ranking of CDY: rating 5
(5 out of 5)
COMPANY WEBSITE:

 

REGISTRY:

Automic Group
Level 5, 191 ST GEORGES TERRACE PERTH WA 6000
Tel : +61 (2) 8072 1400 or 1300 288 664 (within Australia)
RegistryWebsite RegistryEmail

Company details

ISIN: AU000000CDY3
Address: Suite 204 Level 2, 55 Clarence Street Sydney NSW 2000 Australia
Tel:  +612 9221 6830Fax: +612 9221 8535

Date first listed: 09/12/2005
Company Secretary: Raymond Ting
Sector: Pharmaceuticals & Biotechnology Industry Group: XHJ
Activities: Developer of products to treat various cancers and chronic inflammatory diseases

News & Events

Expand this box to read and print

name changed to Anagenics Limited

15/12/2021

The suspension of trading in the securities of Cellmid Limited will be lifted immediately, following the release by CDY, announcements responding to a media article and regarding the testing results conducted by the Peter Doherty Institute for Infection and Immunity.

15/06/2020

The company reports on results of the Doherty Institute testing.

15/06/2020

Cellmid signed an Introducer Agreement with Emergence Technology Pty Ltd securing access to additional SARS-CoV-2 tests for its customers. Emergence is responsible for the supply of the Tests. The Tests are available to Emergence globally. The Agreement allows for the payment of a Commission to Cellmid in relation to sales on introductions it makes to potential customers.

04/06/2020

The company releases the Results of Meeting.

21/05/2020

The company releases its General Meeting Presentation.

21/05/2020

Considering the increased media coverage and confusion in relation to the SARSCoV-2 POCTs Cellmid has decided that, pursuant to ASX Listing Rule 17.2, it would be prudent to request an extension of the voluntary suspension of its securities until the Doherty Review results are received.

15/05/2020

The Board of Cellmid Limited have made the decision that, in the interests of safety, physical attendance by shareholders will not be permitted at the upcoming General Meeting being held at 2pm (AEST) on Thursday, 21 May 2020. Cellmid are making the meeting available to shareholders via zoom and shareholders wishing to attend in this manner are asked to register their interest by sending an email to egm@cellmid.com.au. Requests to attend the meeting by zoom must be received by 7pm (AEST) on Tuesday, 19 May 2020.

14/05/2020

The securities of Cellmid Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of CDY, pending the release of an announcement in response to a media article.

11/05/2020

The suspension of trading in the securities of Cellmid Limited will be lifted immediately, following the release by CDY of an announcement regarding a capital raising.

07/04/2020

The company issues a notice of Proposed issue of Securities - CDY.

07/04/2020

Cellmid has raised $6 million (before costs) via a share placement from institutional and sophisticated investors. Existing shareholders will have the opportunity to participate on the same terms via a Share Purchase Plan targeting an additional $1.0 million. Proceeds raised under the offer will be used to fund the roll out of the Wondfo SARS-V-2 diagnostic test.

07/04/2020

The company issues a response to ASX Query Letter.

06/04/2020

The securities of Cellmid Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of CDY, pending the release of an announcement regarding a proposed capital raising.

06/04/2020

The suspension of trading in the securities of Cellmid Limited will be lifted from the commencement of trading on Monday, 30 March 2020, following the release by CDY of an announcement regarding a new material supply agreement.

27/03/2020

Sales of the Company's consumer health products in Australia and Japan have been moderately impacted over the past few weeks. Australia, representing around 23% of sales historically, performed well until the end of February, however, the product launch planned for March in Priceline has been delayed, which will start effecting sales from April onwards locally. Operational expenditure of the Company is carefully monitored and reduced where sensible. The Company has been exploring new product lines that can bring additional revenues in the near term. Research and development activities have not been affected to date. The Company has determined that it is prudent to withdraw its previous guidance that it will achieve operational profitability for its consumer business by the end of FY2020, and will separate Lyramid into a wholly independent entity backed by independent funding and/or a partnership with a biopharmaceutical company by the end of 2020.

27/03/2020

Cellmid signs a supply agreement for a COVID-19 rapid diagnostic test with the Australian agent of a Therapeutic Good Administration certified Chinese manufacturer. The COVID-19 rapid diagnostic test is CE Marked, TGA and NMPA (National Medical Products Administration) approved . The test uses virus specific IgG/IgM detection method returning results quickly, and no requirement for PCR (Polymerase Chain Reaction) equipment . The test is available immediately and is suitable as a bedside test, can be used in hospitals, nursing homes, schools, remote areas and by corporates when administered by healthcare professionals as well as in pathology labs.

27/03/2020

The securities of Cellmid Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of CDY, pending the release of an announcement regarding a new material supply agreement.

24/03/2020

we understand that on or about this date the company consolidated its shares 1 for 20

05/12/2017

The securities of Cellmid Limited will be reinstated to official quotation immediately today, Tuesday 1 November 2016, in accordance with listing rule 17.7, following lodgement of an announcement in relation to the completion of a capital raising by the Company.

01/11/2016

The company received commitments totalling $3 million, for new fully paid shares in the Company at 3 cents per Placement Share (the Placement). The Placement was supported by new institutional and sophisticated investors as well as existing shareholders. The Company will use the funds raised to launch the evolis® FGF5 inhibitor hair growth products in the US market.

01/11/2016

The company lodges its Appendix 4C - quarterly report.

31/10/2016

The securities of Cellmid Limited will be suspended from quotation immediately, at the request of the Company in accordance with Listing Rule 17.2.

28/10/2016

name changed from Medical Therapies Limited

20/11/2009

 

Click here for free access to this company's:
ASX, Legal & CGT Status

Your comments

Please read our Terms before viewing comments.

 

Company Updates

Post your comments here

Please read our Terms before posting comments.
OMISSIONS
    You can post a comment here about this company

    Please click in the "I'm not a robot" box and enter the word/figures you see in the image that then appears.

    loading Posting your comments. Please wait...

     


     

    Click here for free access to this company's:
    ASX, Legal & CGT Status

    Directors' on-market share transactions (last 5)

    rss feeds

    Purchases Sales

    DATEDIRECTORNUMBERPRICEAMOUNT
    22/09/2021Maria Halasz362,361$0.056$20,111
    22/06/2020Maria Halasz152,789$0.115$17,571
    31/05/2019Maria Halasz12,000$0.190$2,280
    29/04/2019Maria Halasz39,000$0.210$8,190
    13/11/2018Maria Halasz22,130$0.350$7,745

    Click here for the last 20 transactions all companies

    Directors & Executives (current)

    NAMETITLEDATE OF APPT
    Bruce GordonChairman, Independent Director01/07/2015
    Maria HalaszManaging Director, CEO16/04/2007
    Dominic BurgCOO01/07/2020
    Martin CrossNon Exec Director16/10/2017
    Phillip ChristopherNon Exec Director05/11/2021
    Dennis EckNon Exec Director26/03/2018
    Sarah Eck-ThompsonAlternate Director21/10/2020

    Date of first appointment, title may have changed.

    Directors & Executives (former)

    NAMETITLEDATE OF APPOINTMENTDATE OF RESIGNATION
    David KingNon Exec Chairman18/01/200831/12/2020
    Fintan WaltonNon Exec Director21/07/201530/11/2020
    Graeme KaufmanNon Exec Director27/08/201230/06/2015
    Martin RogersNon Exec Director19/09/201230/06/2015
    Robin BeaumontNon Exec Director12/10/200927/08/2012
    Koichiro KoikeDirector09/12/2010
    Stephanie WilliamsExecutive Director15/02/200826/08/2008
    Michael TavernerNon Exec Director08/10/200415/02/2008
    Michael VitaleChairman16/12/200418/01/2008
    Malcom CastleNon Exec Director23/02/200621/05/2007
    Llewellyn CasboltManaging Director16/12/200415/11/2006
    James DominguezChairman16/12/200409/03/2006

    Date of first appointment, title may have changed.